Redeye retains its positive stance on Xbrane following today’s release of the year-end report. The company has announced a non-binding term-sheet for divestment of its subsidiary, allowing complete focus on the biosimilar field. After taking part of the year-end report, we are left with a feeling of optimism and argue Xbrane is in a strong position.